BACKGROUND: Late April 2009, human infection with variant influenza virus A(H1N1)v emerged in the Northern Americas posing a threat that this virus may become the next pandemic influenza virus. OBJECTIVES: To prepare laboratories for surge capacity for molecular diagnosis of patients suspected for A(H1N1)v infection in the Netherlands. STUDY DESIGN: A panel of 10 blinded specimens containing seasonal A(H1N1) or A(H3N2), or A/Netherlands/602/2009(H1N1)v influenza virus, or negative control was distributed to the outbreak assistance laboratories (OAL) together with influenza virus A (M-gene), swine influenza virus A (NP-gene) and influenza virus A(H1N1)v (H1v-gene) specific primers and probes and protocol (CDC Atlanta, USA). Laboratories were asked to implement and test this protocol. RESULTS: All OAL were able to detect A(H1N1)v using the CDC M-gene reagents, the majority with similar sensitivity as the in-house M-gene based assays. RT-PCRs used in routine diagnostic setting in the OAL specifically designed to detect H1, H3, or NS1 from seasonal influenza A viruses, did not or at very low level cross-react with A(H1N1)v. The CDC swine NP-gene and H1v-gene RT-PCRs showed somewhat reduced sensitivity compared to the CDC and in-house M-gene RT-PCRs. In contrast, in-house developed A(H1N1)v specific H1v-gene and N1v-gene RT-PCRs showed equal sensitivity to CDC and in-house M-gene RT-PCRs. CONCLUSIONS: The Dutch OAL are prepared for detection and specific identification of A(H1N1)v, although some level of cross-reactivity was observed with seasonal influenza viruses. Additionally, M-gene based generic influenza A virus detection is recommended to be able to detect emerging influenza A viruses in routine settings.
BACKGROUND: Late April 2009, human infection with variant influenza virus A(H1N1)v emerged in the Northern Americas posing a threat that this virus may become the next pandemic influenza virus. OBJECTIVES: To prepare laboratories for surge capacity for molecular diagnosis of patients suspected for A(H1N1)v infection in the Netherlands. STUDY DESIGN: A panel of 10 blinded specimens containing seasonal A(H1N1) or A(H3N2), or A/Netherlands/602/2009(H1N1)v influenza virus, or negative control was distributed to the outbreak assistance laboratories (OAL) together with influenza virus A (M-gene), swine influenza virus A (NP-gene) and influenza virus A(H1N1)v (H1v-gene) specific primers and probes and protocol (CDC Atlanta, USA). Laboratories were asked to implement and test this protocol. RESULTS: All OAL were able to detect A(H1N1)v using the CDC M-gene reagents, the majority with similar sensitivity as the in-house M-gene based assays. RT-PCRs used in routine diagnostic setting in the OAL specifically designed to detect H1, H3, or NS1 from seasonal influenza A viruses, did not or at very low level cross-react with A(H1N1)v. The CDC swine NP-gene and H1v-gene RT-PCRs showed somewhat reduced sensitivity compared to the CDC and in-house M-gene RT-PCRs. In contrast, in-house developed A(H1N1)v specific H1v-gene and N1v-gene RT-PCRs showed equal sensitivity to CDC and in-house M-gene RT-PCRs. CONCLUSIONS: The Dutch OAL are prepared for detection and specific identification of A(H1N1)v, although some level of cross-reactivity was observed with seasonal influenza viruses. Additionally, M-gene based generic influenza A virus detection is recommended to be able to detect emerging influenza A viruses in routine settings.
Authors: M L B Hillaire; S E van Trierum; R Bodewes; C A van Baalen; R S van Binnendijk; M P Koopmans; R A M Fouchier; A D M E Osterhaus; G F Rimmelzwaan Journal: J Virol Date: 2011-09-14 Impact factor: 5.103
Authors: Michiel van Boven; Tjibbe Donker; Mariken van der Lubben; Rianne B van Gageldonk-Lafeber; Dennis E te Beest; Marion Koopmans; Adam Meijer; Aura Timen; Corien Swaan; Anton Dalhuijsen; Susan Hahné; Anneke van den Hoek; Peter Teunis; Marianne A B van der Sande; Jacco Wallinga Journal: PLoS One Date: 2010-07-07 Impact factor: 3.240
Authors: Arianne B van Gageldonk-Lafeber; Marianne Ab van der Sande; Adam Meijer; Ingrid Hm Friesema; Gé A Donker; Johan Reimerink; Mirna Robert-Du Ry van Beest Holle; Jan M Prins; Leslie Isken; François G Schellevis; Mariken Im van der Lubben Journal: Antimicrob Resist Infect Control Date: 2012-09-21 Impact factor: 4.887
Authors: Anneke Steens; Eleonora G Wijnans; Jeanne P Dieleman; Miriam Cjm Sturkenboom; Marianne Ab van der Sande; Wim van der Hoek Journal: BMC Infect Dis Date: 2011-07-18 Impact factor: 3.090
Authors: Ingrid H M Friesema; Adam Meijer; Arianne B van Gageldonk-Lafeber; Mariken van der Lubben; Janko van Beek; Gé A Donker; Jan M Prins; Menno D de Jong; Simone Boskamp; Leslie D Isken; Marion P G Koopmans; Marianne A B van der Sande Journal: Influenza Other Respir Viruses Date: 2012-02-28 Impact factor: 4.380
Authors: Marit M A de Lange; Adam Meijer; Ingrid H M Friesema; Gé A Donker; Carl E Koppeschaar; Mariëtte Hooiveld; Nel Ruigrok; Wim van der Hoek Journal: BMC Public Health Date: 2013-09-24 Impact factor: 3.295
Authors: Jairo Gooskens; Jessika C Zevenhoven-Dobbe; Eric C Claas; Aloys C M Kroes; Clara C Posthuma Journal: PLoS One Date: 2014-04-03 Impact factor: 3.240